

Hemophilia A

What is AHA?

- Acquired Hemophilia A (AHA) is a rare bleeding disorder characterized by abnormal, uncontrolled bleeding.1
- Under normal circumstances, when bleeding occurs in the body, proteins known as clotting factors help clot the blood at that specific location to stop the bleed. 1
- Patients with AHA develop antibodies that inactivate a specific clotting factor (Factor VIII [FVIII]).1
- When FVIII activity is decreased, blood does not clot properly, and the patient can bleed easily.1
- AHA occurs in patients with no personal or family history of hemorrhages. It therefore cannot be passed down to children or grandchildren.1

48% of study patients developed AHA due to an underlying cause, such as a malignancy or autoimmune disorder. In the other 52%, the cause was unknown.2



Who does AHA affect?

- Per year in Canada, AHA affects 0.3-14.7 people aged 16 or over per million. The chance of developing AHA increases with age.3
- AHA tends to occur in older individuals.⁴
- Younger women can also develop AHA after giving birth (during the post-partum period).4

In one study, AHA was shown to affect men and women almost equally.3



Results based on a European survey conducted between 2003 and 2008.



What are common symptoms of AHA?

- People with AHA often experience severe bleeding, which can occur spontaneously (without an apparent cause) or following trauma (e.g. an injury or surgery).¹
- Symptoms of AHA include:^{1,4}
 - Bleeding under the skin (bruising)
 - Nosebleeds
 - Blood in the urine, stool, mouth or phlegm
 - Swelling or skin discoloration in the joint areas, which may cause limited mobility

How is AHA managed/treated?

Acquired Hemophilia A is a disease in which antibodies, specialized proteins involved in immune response, attack the clotting factors which help blood clot.^{1,4}

The goals for AHA management may include:

- 1 Stopping/controlling the bleeding
- 2 Eliminating the antibodies that reduce the number of clotting factors
- Treatment for AHA should be personalized to each unique patient; speak to your healthcare professional to find out what treatment is best for you.



Are there any types of medications I should avoid if I have AHA?

- Some pain medications can worsen bleeding. It is recommended to consult your doctor prior to taking any medication.⁵
- Blood-thinning medication prevents blood from clotting properly. Ask your doctor about what these may be.⁵



What do I do in case of relapse?

- Since AHA is caused by a temporary malfunctioning of the immune system, remission can occur.⁶
- While the definition of remission can vary, it typically means FVIII levels are normal, there are no detectable antibodies against FVIII and therapies have been stopped.^{6,7}
- Relapse may still occur after remission is achieved.⁶

A Québec study observed about 14% of people experienced at least one relapse following remission.⁶



- According to this study, relapsing patients tended to be older.⁶
- People who relapsed typically responded well to further treatment and their relapse(s) was(were) not associated with a worse overall survival.⁶

If you experience symptoms after stopping or reducing therapy, contact your doctor immediately.

References:

- NORD: National Organization for Rare Disorders. Acquired Hemophilia [last modified 2016; cited 2021 Feb 8]. Available from: https:// rarediseases.org/rare-diseases/acquired-hemophilia/.
- Knoebl P, Marco P, Baudo F, et al. Demographic and clinical data in acquired hemophilia A: results from the European Acquired Hemophilia Registry (EACH2). J Thromb Haemost. 2021;10: 622–31.
- Mazzucconi MG, Baldacci E, Ferretti A et al. Acquired Haemophilia A: An Intriguing Disease. Mediterr J Hematol Infect Dis. 2020;12(1):e2020045.
- Canadian Hemophilia Society/Canadian Association of Nurses in Hemophilia Care. Acquired Hemophilia Infographic [published 2017 Oct; cited 2021 Feb 9]. Available from: https://www.hemophilia.ca/files/Acquired%20hemophilia%202017.pdf.
- Mayo Clinic. Hemophilia [last modified 2020 Aug; cited Feb 11].
 Available from: https://www.mayoclinic.org/diseases-conditions/hemophilia/diagnosis-treatment/drc-20373333.
- Mizrahi T, Doyon K, Dube E, et al. Relapse pattern and long-term outcomes in subjects with acquired haemophilia A. Haemophilia. 2019;25:252-7.
- Trossaert M, Graveleau J, Thiercelin-Legrand MF, et al. The factor VIII:C/VWG:Ag ratio as a useful tool to predict relapse in patients with acquired haemophilia A: A retrospective cohort study. Haemophilia. 2019;25:527-34.

